Medical Crossfire®: Expert Perspectives in Sustained Delivery of Anti-VEGF Therapies – Understanding How Novel Treatments May Shift the Paradigm

CME: 1.5

Target Audience

This online educational activity is directed toward ophthalmologists and retinal specialists. Other health care professionals involved in the treatment of patients with nAMD are also invited to participate.

Program Overview

Medical Crossfire™, one of PER’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions about a clinical topic. In this activity, four thought leaders explore the emerging data surrounding sustained-delivery anti-vascular endothelial growth factor (Anti-VEGF) therapies for the management of neovascular retinal diseases like neovascular age-related macular degeneration (nAMD). This lively debate will place new developments into clinical context to help you optimize care for patients with neovascular retinal diseases.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the unmet clinical needs for durable, sustained treatment options for patients with AMD
  • Analyze the efficacy and safety data for novel sustained delivery options of anti-VEGF therapies for the treatment of AMD
  • Incorporate novel sustained delivery options of anti-VEGF therapies into management plans for patients with AMD

Post a comment to this article